Literature DB >> 28468865

Cell-Free DNA from Ascites and Pleural Effusions: Molecular Insights into Genomic Aberrations and Disease Biology.

Hatim Husain1, David Nykin2, Nam Bui2, Daniel Quan2, German Gomez2, Brian Woodward2, Sumathi Venkatapathy3, Radha Duttagupta3, Eric Fung3, Scott M Lippman2, Razelle Kurzrock2.   

Abstract

Collection of cell-free DNA (cfDNA) from the blood of individuals with cancer has permitted noninvasive tumor genome analysis. Detection and characterization of cfDNA in ascites and pleural effusions have not yet been reported. Herein, we analyzed cfDNA in the ascites and pleural effusions from six individuals with metastatic cancer. In all cases, cfDNA copy number variations (CNV) were discovered within the effusate. One individual had a relevant alteration with a high copy amplification in EGFR in a never smoker with lung cancer, who showed only MDM2 and CDK4 amplification in a prior tissue biopsy. Another subject with metastatic breast cancer had cytology-positive ascites and an activating PIK3CA mutation identified in the tissue, blood, and ascites collectively. This individual had tumor regression after the administration of the mTOR inhibitor everolimus and had evidence of chromotripsis from chromosomal rearrangements noted in the cell-free ascitic fluid. These results indicate that cfDNA from ascites and pleural effusions may provide additional information not detected with tumor and plasma cell-free DNA molecular characterization, and a context for important insights into tumor biology and clonal dynamic change within primary tumor and metastatic deposits. Mol Cancer Ther; 16(5); 948-55. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28468865     DOI: 10.1158/1535-7163.MCT-16-0436

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  29 in total

Review 1.  Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA).

Authors:  Re-I Chin; Kevin Chen; Abul Usmani; Chanelle Chua; Peter K Harris; Michael S Binkley; Tej D Azad; Jonathan C Dudley; Aadel A Chaudhuri
Journal:  Mol Diagn Ther       Date:  2019-06       Impact factor: 4.074

Review 2.  Clinical cancer genomic profiling.

Authors:  Debyani Chakravarty; David B Solit
Journal:  Nat Rev Genet       Date:  2021-03-24       Impact factor: 53.242

Review 3.  Liquid biopsy, a paradigm shift in oncology: what interventional radiologists should know.

Authors:  Marco Calandri; Giulia Siravegna; Andrea Veltri; Bruno C Odisio; Steven M Yevich; Giuseppe Stranieri; Carlo Gazzera; Scott Kopetz; Paolo Fonio; Sanjay Gupta; Alberto Bardelli
Journal:  Eur Radiol       Date:  2020-03-19       Impact factor: 5.315

4.  Optimizing Nanopore sequencing-based detection of structural variants enables individualized circulating tumor DNA-based disease monitoring in cancer patients.

Authors:  Jose Espejo Valle-Inclan; Christina Stangl; Anouk C de Jong; Lisanne F van Dessel; Markus J van Roosmalen; Jean C A Helmijr; Ivo Renkens; Roel Janssen; Sam de Blank; Chris J de Witte; John W M Martens; Maurice P H M Jansen; Martijn P Lolkema; Wigard P Kloosterman
Journal:  Genome Med       Date:  2021-05-18       Impact factor: 11.117

Review 5.  The untapped potential of ascites in ovarian cancer research and treatment.

Authors:  Caroline Elizabeth Ford; Bonnita Werner; Neville Frederick Hacker; Kristina Warton
Journal:  Br J Cancer       Date:  2020-05-08       Impact factor: 7.640

6.  1H-NMR spectroscopy metabonomics of reactive, ovarian carcinoma and hepatocellular carcinoma ascites.

Authors:  Lucio Zennaro; Lorenzo Nicolè; Paola Vanzani; Filippo Cappello; Ambrogio Fassina
Journal:  Pleura Peritoneum       Date:  2020-05-12

7.  JAK2 V617F mutation in plasma cell-free DNA preceding clinically overt myelofibrosis: Implications for early diagnosis.

Authors:  Michael Y Choi; Shumei Kato; Huan-You Wang; Jonathan H Lin; Richard B Lanman; Razelle Kurzrock
Journal:  Cancer Biol Ther       Date:  2018-08-03       Impact factor: 4.742

8.  Cell-free DNA From Pleural Effusion Samples: Is It Right for Molecular Testing in Lung Adenocarcinoma?

Authors:  Attila Mokánszki; Emese Sarolta Bádon; Anikó Mónus; László Tóth; Nóra Bittner; Gábor Méhes
Journal:  Pathol Oncol Res       Date:  2021-03-30       Impact factor: 3.201

9.  Mobile element insertions and associated structural variants in longitudinal breast cancer samples.

Authors:  Cody J Steely; Kristi L Russell; Julie E Feusier; Yi Qiao; Sean V Tavtigian; Gabor Marth; Lynn B Jorde
Journal:  Sci Rep       Date:  2021-06-22       Impact factor: 4.379

Review 10.  The dawn of the liquid biopsy in the fight against cancer.

Authors:  Irma G Domínguez-Vigil; Ana K Moreno-Martínez; Julia Y Wang; Michael H A Roehrl; Hugo A Barrera-Saldaña
Journal:  Oncotarget       Date:  2017-12-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.